YET another promising Alzheimer's Disease treatment drug has fallen over as Eli Lilly and AstraZeneca ended two late-stage trials of an experimental drug for the disease after the treatment failed to show any signs of working, Bloomberg reports.
Ever elusive, drug treatments for Alzheimer's Disease constantly fail in later phase trials even if successful in early mice studies, the mice model bringing hope but proving to be a disappointing human disease model in this case.
An independent data-monitoring committee found that the medicine, lanabecestat, was unlikely to meet the goals of the studies, one for early Alzheimer's and the other for mild dementia related to the disease, the companies said in a statement this week.
By one count, more than 190 Alzheimer drugs have failed in trials, despite billions spent by pharmaceutical companies on R&D, the report said.
The above article was sent to subscribers in Pharmacy Daily's issue from 14 Jun 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Jun 18
